Target Price | $523.93 |
Price | $463.98 |
Potential | 12.92% |
Number of Estimates | 29 |
29 Analysts have issued a price target Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals target price is $523.93. This is 12.92% higher than the current stock price. The highest price target is $602.00 29.75% , the lowest is $325.00 29.95% . | |
A rating was issued by 36 analysts: 22 Analysts recommend Vertex Pharmaceuticals to buy, 11 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2025 of 12.92% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
30 Analysts have issued a sales forecast Vertex Pharmaceuticals 2024 . The average Vertex Pharmaceuticals sales estimate is $10.9b . This is 2.59% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $11.0b 3.37% , the lowest is $10.8b 2.02% .
This results in the following potential growth metrics:
2023 | $9.8b | 12.47% |
---|---|---|
2024 | $10.9b | 10.71% |
2025 | $11.8b | 8.49% |
2026 | $13.0b | 9.59% |
2027 | $14.1b | 8.98% |
2028 | $15.5b | 10.02% |
8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2024. The average Vertex Pharmaceuticals EBITDA estimate is $865m . This is 1,081.51% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $950m 1,178.70% , the lowest is $801m 1,009.62% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | $4.5b | 5.44% |
---|---|---|
2024 | $865m | 80.61% |
2025 | $5.9b | 583.01% |
2026 | $6.6b | 11.66% |
2027 | $7.3b | 10.28% |
2028 | $8.0b | 10.35% |
2023 | 45.32% | 6.25% |
---|---|---|
2024 | 7.94% | 82.48% |
2025 | 49.98% | 529.47% |
2026 | 50.92% | 1.88% |
2027 | 51.53% | 1.20% |
2028 | 51.68% | 0.29% |
17 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2024. The average Vertex Pharmaceuticals net profit estimate is $-525m . This is 2.40% lower than the net profit for the last 12 months(TTM). The highest net profit forecast is $-361m 29.65% , the lowest is $-876m 70.86% .
This results in the following potential growth metrics and future Net Margins:
2023 | $3.6b | 8.35% |
---|---|---|
2024 | $-525m | 114.67% |
2025 | $4.3b | 913.75% |
2026 | $4.7b | 10.65% |
2027 | $5.3b | 12.92% |
2028 | $6.1b | 14.17% |
2023 | 36.39% | 3.67% |
---|---|---|
2024 | -4.82% | 113.25% |
2025 | 36.17% | 850.41% |
2026 | 36.52% | 0.97% |
2027 | 37.84% | 3.61% |
2028 | 39.26% | 3.75% |
17 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is $-2.04 . This is 2.51% lower than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is $-1.40 29.65% , the lowest is $-3.40 70.85% .
This results in the following potential growth metrics and future valuations:
2023 | $13.89 | 8.35% |
---|---|---|
2024 | $-2.04 | 114.69% |
2025 | $16.58 | 912.75% |
2026 | $18.35 | 10.68% |
2027 | $20.72 | 12.92% |
2028 | $23.66 | 14.19% |
Current | -232.78 | 983.08% |
---|---|---|
2024 | -227.69 | 2.19% |
2025 | 27.98 | 112.29% |
2026 | 25.29 | 9.61% |
2027 | 22.39 | 11.47% |
2028 | 19.61 | 12.42% |
Based on analysts' sales estimates for 2024, the Vertex Pharmaceuticals stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 10.53 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 10.97 .
This results in the following potential growth metrics and future valuations:
Current | 10.80 | 30.28% |
---|---|---|
2024 | 10.53 | 2.54% |
2025 | 9.70 | 7.83% |
2026 | 8.85 | 8.75% |
2027 | 8.12 | 8.24% |
2028 | 7.38 | 9.11% |
Current | 11.25 | 19.01% |
---|---|---|
2024 | 10.97 | 2.53% |
2025 | 10.11 | 7.83% |
2026 | 9.23 | 8.75% |
2027 | 8.47 | 8.24% |
2028 | 7.70 | 9.11% |
Vertex Pharmaceuticals...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.